STOCK TITAN

[8-K] Oncocyte Corporation Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Synchrony Financial (SYF) filed a Form 4 on 2 Jul 2025 disclosing a routine equity award to director Fernando Aguirre. On 30 Jun 2025 Aguirre received 825 restricted stock units (RSUs) classified under transaction code “A” (grant). The filing lists an indicative price of $66.74, though RSUs do not require cash payment. The award will vest in full on 30 Jun 2026; each RSU converts into one share of SYF common stock.

Following the grant, Aguirre’s direct ownership rises to 27,097 common shares. He also reports 15,300 shares held indirectly through family trusts, bringing his total reported economic exposure to 42,397 shares. No open-market purchases, sales, or derivative transactions were reported, and there were no amendments to previous filings.

The size of the award represents a modest increase—roughly 3% of Aguirre’s previously reported direct holdings and an immaterial fraction of SYF’s ~420 million shares outstanding. As such, the transaction is viewed as a standard board compensation event that marginally aligns director incentives with shareholder interests but carries no material impact on the company’s capital structure or valuation.

Synchrony Financial (SYF) ha presentato un Modulo 4 il 2 luglio 2025, comunicando un premio azionario ordinario al direttore Fernando Aguirre. Il 30 giugno 2025 Aguirre ha ricevuto 825 unità azionarie vincolate (RSU) classificate con il codice transazione “A” (concessione). Il documento indica un prezzo indicativo di 66,74 $, anche se le RSU non richiedono pagamento in contanti. Il premio maturerà completamente il 30 giugno 2026; ogni RSU si convertirà in un'azione ordinaria SYF.

Dopo la concessione, la proprietà diretta di Aguirre sale a 27.097 azioni ordinarie. Riporta inoltre 15.300 azioni detenute indirettamente tramite trust familiari, portando la sua esposizione economica totale a 42.397 azioni. Non sono stati segnalati acquisti, vendite o transazioni derivati sul mercato aperto, né modifiche a precedenti comunicazioni.

La dimensione del premio rappresenta un aumento modesto—circa il 3% delle partecipazioni dirette precedentemente dichiarate da Aguirre e una frazione irrilevante delle ~420 milioni di azioni in circolazione di SYF. Pertanto, l’operazione è considerata un evento standard di compensazione del consiglio che allinea marginalmente gli incentivi del direttore con gli interessi degli azionisti, senza però avere alcun impatto significativo sulla struttura del capitale o sulla valutazione della società.

Synchrony Financial (SYF) presentó un Formulario 4 el 2 de julio de 2025 revelando una concesión rutinaria de acciones al director Fernando Aguirre. El 30 de junio de 2025, Aguirre recibió 825 unidades restringidas de acciones (RSU) clasificadas bajo el código de transacción “A” (concesión). El documento indica un precio indicativo de $66.74, aunque las RSU no requieren pago en efectivo. La concesión se consolidará completamente el 30 de junio de 2026; cada RSU se convierte en una acción común de SYF.

Tras la concesión, la propiedad directa de Aguirre aumenta a 27,097 acciones comunes. También reporta 15,300 acciones en propiedad indirecta a través de fideicomisos familiares, sumando una exposición económica total de 42,397 acciones. No se reportaron compras, ventas o transacciones con derivados en el mercado abierto, ni modificaciones a presentaciones previas.

El tamaño de la concesión representa un aumento modesto—aproximadamente un 3% de las participaciones directas previamente reportadas por Aguirre y una fracción insignificante de las aproximadamente 420 millones de acciones en circulación de SYF. Por lo tanto, la transacción se considera un evento estándar de compensación del consejo que alinea marginalmente los incentivos del director con los intereses de los accionistas, pero que no tiene impacto material en la estructura de capital o valoración de la empresa.

Synchrony Financial(SYF)는 2025년 7월 2일 이사 페르난도 아귀레에 대한 정기 주식 보상을 공개하는 Form 4를 제출했습니다. 2025년 6월 30일 아귀레는 거래 코드 “A”(부여)로 분류된 825개의 제한 주식 단위(RSU)를 받았습니다. 제출서류에는 66.74달러의 표시 가격이 기재되어 있으나 RSU는 현금 지불이 필요하지 않습니다. 이 보상은 2026년 6월 30일에 완전히 취득되며, 각 RSU는 SYF 보통주 1주로 전환됩니다.

보상 후 아귀레의 직접 소유 주식 수27,097주로 증가했습니다. 또한 가족 신탁을 통해 15,300주를 간접 보유하고 있어 총 경제적 노출은 42,397주입니다. 공개 시장에서의 매매나 파생상품 거래는 보고되지 않았으며, 이전 제출서류의 수정도 없었습니다.

이번 보상 규모는 아귀레가 이전에 보고한 직접 보유 주식의 약 3%에 해당하는 소폭 증가이며, SYF의 약 4억 2천만 주 발행 주식 중 미미한 비율에 불과합니다. 따라서 이 거래는 이사 보상 관련 표준 행사로 간주되며, 이사의 인센티브를 주주 이익과 소폭 일치시키지만 회사의 자본 구조나 가치 평가에는 중대한 영향이 없습니다.

Synchrony Financial (SYF) a déposé un formulaire 4 le 2 juillet 2025, révélant une attribution d’actions de routine au directeur Fernando Aguirre. Le 30 juin 2025, Aguirre a reçu 825 unités d’actions restreintes (RSU) classées sous le code de transaction « A » (attribution). Le document indique un prix indicatif de 66,74 $, bien que les RSU ne nécessitent pas de paiement en espèces. L’attribution sera entièrement acquise le 30 juin 2026 ; chaque RSU se convertit en une action ordinaire SYF.

Après cette attribution, la possession directe d’Aguirre passe à 27 097 actions ordinaires. Il déclare également 15 300 actions détenues indirectement via des trusts familiaux, portant son exposition économique totale à 42 397 actions. Aucun achat, vente ou transaction dérivée sur le marché ouvert n’a été signalé, et aucune modification aux déclarations précédentes n’a été apportée.

La taille de l’attribution représente une augmentation modeste—environ 3 % des avoirs directs précédemment déclarés par Aguirre et une fraction négligeable des quelque 420 millions d’actions en circulation de SYF. Ainsi, la transaction est considérée comme un événement standard de rémunération du conseil, alignant marginalement les incitations du directeur sur les intérêts des actionnaires, mais sans impact matériel sur la structure du capital ou la valorisation de l’entreprise.

Synchrony Financial (SYF) reichte am 2. Juli 2025 ein Formular 4 ein, das eine routinemäßige Aktienzuteilung an den Direktor Fernando Aguirre offenlegt. Am 30. Juni 2025 erhielt Aguirre 825 Restricted Stock Units (RSUs), klassifiziert unter dem Transaktionscode „A“ (Gewährung). Die Einreichung nennt einen indikativem Preis von 66,74 $, obwohl für RSUs keine Barzahlung erforderlich ist. Die Zuteilung wird am 30. Juni 2026 vollständig erworben; jede RSU wird in eine Aktie der SYF-Stammaktien umgewandelt.

Nach der Zuteilung steigt Aguirres direkter Besitz auf 27.097 Stammaktien. Er meldet außerdem 15.300 indirekt über Familienstiftungen gehaltene Aktien, was seine insgesamt gemeldete wirtschaftliche Beteiligung auf 42.397 Aktien erhöht. Es wurden keine Käufe, Verkäufe oder Derivatgeschäfte am offenen Markt gemeldet, und es gab keine Änderungen an früheren Meldungen.

Die Größe der Zuteilung stellt eine moderate Erhöhung dar—etwa 3 % von Aguirres zuvor gemeldeten direkten Beständen und einen unbedeutenden Bruchteil der rund 420 Millionen ausstehenden SYF-Aktien. Daher wird die Transaktion als ein standardmäßiges Vorstandsvergütungsereignis betrachtet, das die Anreize des Direktors marginal mit den Interessen der Aktionäre in Einklang bringt, jedoch keine wesentlichen Auswirkungen auf die Kapitalstruktur oder Bewertung des Unternehmens hat.

Positive
  • None.
Negative
  • None.

Insights

TL;DR – Minor RSU grant to SYF director; neutral for valuation.

The Form 4 shows a straightforward equity compensation grant: 825 RSUs at an implied $66.74, vesting in one year. Post-grant, Aguirre owns 0.006% of outstanding shares—too small to affect float or insider-ownership metrics. Because the award was issued by the company (code A) rather than bought in the open market, it does not signal incremental insider confidence beyond routine board pay. I therefore classify the filing as neutral with no expected trading impact.

TL;DR – Routine director compensation; reinforces alignment, but not impactful.

Annual RSU grants are common for S&P 500 financial issuers and support long-term alignment with shareholders. The single-year cliff vesting encourages at least 12 months of continued service. No accelerated vesting, performance hurdles, or derivative overlays were disclosed, indicating a vanilla structure. Governance takeaway: compensation practices remain standard; no red flags or exceptional incentives were introduced.

Synchrony Financial (SYF) ha presentato un Modulo 4 il 2 luglio 2025, comunicando un premio azionario ordinario al direttore Fernando Aguirre. Il 30 giugno 2025 Aguirre ha ricevuto 825 unità azionarie vincolate (RSU) classificate con il codice transazione “A” (concessione). Il documento indica un prezzo indicativo di 66,74 $, anche se le RSU non richiedono pagamento in contanti. Il premio maturerà completamente il 30 giugno 2026; ogni RSU si convertirà in un'azione ordinaria SYF.

Dopo la concessione, la proprietà diretta di Aguirre sale a 27.097 azioni ordinarie. Riporta inoltre 15.300 azioni detenute indirettamente tramite trust familiari, portando la sua esposizione economica totale a 42.397 azioni. Non sono stati segnalati acquisti, vendite o transazioni derivati sul mercato aperto, né modifiche a precedenti comunicazioni.

La dimensione del premio rappresenta un aumento modesto—circa il 3% delle partecipazioni dirette precedentemente dichiarate da Aguirre e una frazione irrilevante delle ~420 milioni di azioni in circolazione di SYF. Pertanto, l’operazione è considerata un evento standard di compensazione del consiglio che allinea marginalmente gli incentivi del direttore con gli interessi degli azionisti, senza però avere alcun impatto significativo sulla struttura del capitale o sulla valutazione della società.

Synchrony Financial (SYF) presentó un Formulario 4 el 2 de julio de 2025 revelando una concesión rutinaria de acciones al director Fernando Aguirre. El 30 de junio de 2025, Aguirre recibió 825 unidades restringidas de acciones (RSU) clasificadas bajo el código de transacción “A” (concesión). El documento indica un precio indicativo de $66.74, aunque las RSU no requieren pago en efectivo. La concesión se consolidará completamente el 30 de junio de 2026; cada RSU se convierte en una acción común de SYF.

Tras la concesión, la propiedad directa de Aguirre aumenta a 27,097 acciones comunes. También reporta 15,300 acciones en propiedad indirecta a través de fideicomisos familiares, sumando una exposición económica total de 42,397 acciones. No se reportaron compras, ventas o transacciones con derivados en el mercado abierto, ni modificaciones a presentaciones previas.

El tamaño de la concesión representa un aumento modesto—aproximadamente un 3% de las participaciones directas previamente reportadas por Aguirre y una fracción insignificante de las aproximadamente 420 millones de acciones en circulación de SYF. Por lo tanto, la transacción se considera un evento estándar de compensación del consejo que alinea marginalmente los incentivos del director con los intereses de los accionistas, pero que no tiene impacto material en la estructura de capital o valoración de la empresa.

Synchrony Financial(SYF)는 2025년 7월 2일 이사 페르난도 아귀레에 대한 정기 주식 보상을 공개하는 Form 4를 제출했습니다. 2025년 6월 30일 아귀레는 거래 코드 “A”(부여)로 분류된 825개의 제한 주식 단위(RSU)를 받았습니다. 제출서류에는 66.74달러의 표시 가격이 기재되어 있으나 RSU는 현금 지불이 필요하지 않습니다. 이 보상은 2026년 6월 30일에 완전히 취득되며, 각 RSU는 SYF 보통주 1주로 전환됩니다.

보상 후 아귀레의 직접 소유 주식 수27,097주로 증가했습니다. 또한 가족 신탁을 통해 15,300주를 간접 보유하고 있어 총 경제적 노출은 42,397주입니다. 공개 시장에서의 매매나 파생상품 거래는 보고되지 않았으며, 이전 제출서류의 수정도 없었습니다.

이번 보상 규모는 아귀레가 이전에 보고한 직접 보유 주식의 약 3%에 해당하는 소폭 증가이며, SYF의 약 4억 2천만 주 발행 주식 중 미미한 비율에 불과합니다. 따라서 이 거래는 이사 보상 관련 표준 행사로 간주되며, 이사의 인센티브를 주주 이익과 소폭 일치시키지만 회사의 자본 구조나 가치 평가에는 중대한 영향이 없습니다.

Synchrony Financial (SYF) a déposé un formulaire 4 le 2 juillet 2025, révélant une attribution d’actions de routine au directeur Fernando Aguirre. Le 30 juin 2025, Aguirre a reçu 825 unités d’actions restreintes (RSU) classées sous le code de transaction « A » (attribution). Le document indique un prix indicatif de 66,74 $, bien que les RSU ne nécessitent pas de paiement en espèces. L’attribution sera entièrement acquise le 30 juin 2026 ; chaque RSU se convertit en une action ordinaire SYF.

Après cette attribution, la possession directe d’Aguirre passe à 27 097 actions ordinaires. Il déclare également 15 300 actions détenues indirectement via des trusts familiaux, portant son exposition économique totale à 42 397 actions. Aucun achat, vente ou transaction dérivée sur le marché ouvert n’a été signalé, et aucune modification aux déclarations précédentes n’a été apportée.

La taille de l’attribution représente une augmentation modeste—environ 3 % des avoirs directs précédemment déclarés par Aguirre et une fraction négligeable des quelque 420 millions d’actions en circulation de SYF. Ainsi, la transaction est considérée comme un événement standard de rémunération du conseil, alignant marginalement les incitations du directeur sur les intérêts des actionnaires, mais sans impact matériel sur la structure du capital ou la valorisation de l’entreprise.

Synchrony Financial (SYF) reichte am 2. Juli 2025 ein Formular 4 ein, das eine routinemäßige Aktienzuteilung an den Direktor Fernando Aguirre offenlegt. Am 30. Juni 2025 erhielt Aguirre 825 Restricted Stock Units (RSUs), klassifiziert unter dem Transaktionscode „A“ (Gewährung). Die Einreichung nennt einen indikativem Preis von 66,74 $, obwohl für RSUs keine Barzahlung erforderlich ist. Die Zuteilung wird am 30. Juni 2026 vollständig erworben; jede RSU wird in eine Aktie der SYF-Stammaktien umgewandelt.

Nach der Zuteilung steigt Aguirres direkter Besitz auf 27.097 Stammaktien. Er meldet außerdem 15.300 indirekt über Familienstiftungen gehaltene Aktien, was seine insgesamt gemeldete wirtschaftliche Beteiligung auf 42.397 Aktien erhöht. Es wurden keine Käufe, Verkäufe oder Derivatgeschäfte am offenen Markt gemeldet, und es gab keine Änderungen an früheren Meldungen.

Die Größe der Zuteilung stellt eine moderate Erhöhung dar—etwa 3 % von Aguirres zuvor gemeldeten direkten Beständen und einen unbedeutenden Bruchteil der rund 420 Millionen ausstehenden SYF-Aktien. Daher wird die Transaktion als ein standardmäßiges Vorstandsvergütungsereignis betrachtet, das die Anreize des Direktors marginal mit den Interessen der Aktionäre in Einklang bringt, jedoch keine wesentlichen Auswirkungen auf die Kapitalstruktur oder Bewertung des Unternehmens hat.

false 0001642380 0001642380 2025-06-27 2025-06-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 27, 2025

 

Insight Molecular Diagnostics Inc.

(Exact name of Registrant as specified in its charter)

 

California   1-37648   27-1041563
(State or other jurisdiction
of incorporation)
  (Commission
File No.)
  (IRS Employer
Identification No.)

 

2 International Plaza Dr., Suite 510

Nashville, Tennessee 37217

(Address of principal executive offices) (Zip code)

 

(949) 409-7600

Registrant’s telephone number, including area code

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities Registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, no par value   IMDX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

General

 

On June 27, 2025, Insight Molecular Diagnostics Inc. (the “Company”) held its 2025 Annual Meeting of Shareholders (the “Annual Meeting”) virtually via live webcast at https://web.lumiconnect.com/259974801. Present at the Annual Meeting virtually or by proxy were holders of 21,008,960 shares of common stock of the Company, which represented 73.46% of the voting power of all shares of common stock of the Company as of May 12, 2025, the record date for the Annual Meeting.

 

Proposals

 

The shareholders of the Company voted on the following proposals at the Annual Meeting, as more fully described in the definitive proxy statement on Schedule 14A relating to the Annual Meeting, which was originally filed with the Securities and Exchange Commission on May 14, 2025 (the “Proxy Statement”):

 

1.To elect the following four (4) director nominees, each to serve until the 2026 annual meeting of shareholders and until his or her successor has been elected and qualified, or until his or her earlier death, resignation, or removal: Joshua Riggs, Andrew Arno, Andrew J. Last and Louis E. Silverman;

 

2.To ratify the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2025

 

3.To approve, on a non-binding advisory basis, the Company’s named executive officer compensation for the year ended December 31, 2024; and

 

4.To approve an amendment to the Company’s Amended and Restated 2018 Equity Incentive Plan to increase the total number of shares of the Company’s common stock authorized for issuance under such plan by 1,500,000, to a total of 3,800,000 shares.

 

Voting Results

 

The final voting results for each of these proposals at the Annual Meeting are detailed below.

 

1. Election of Directors

 

      Shares Voted 
Director Nominee  For  Against  Abstained  Broker Non-Votes 
Joshua Riggs   18,094,181   6,225   3,890   2,904,664 
Andrew Arno   18,033,599   66,567   4,130   2,904,664 
Andrew J. Last   18,041,724   58,642   3,930   2,904,664 
Louis E. Silverman   18,035,578   64,816   3,902   2,904,664 
                  

 

Based on the votes set forth above, each director nominee was duly elected to serve until the 2026 annual meeting of shareholders and until his or her successor has been elected and qualified, or until his or her earlier death, resignation, or removal.

 

2. Ratification of Appointment of Accounting Firm

 

Shares Voted
For  Against  Abstained  Broker Non-Votes
20,986,994  4,951  17,015  0

 

Based on the votes set forth above, the shareholders ratified the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2025.

 

 

 

 

3. Say On Pay Proposal

 

Shares Voted
For  Against  Abstained  Broker Non-Votes
18,063,639  28,647  12,010  2,904,664

 

Based on the votes set forth above, the shareholders approved, on a non-binding advisory basis, the Company’s named executive officer compensation for the year ended December 31, 2024.

 

4. Approval of Amendment to Amended and Restated Incentive Plan

 

Shares Voted
For  Against  Abstained  Broker Non-Votes
17,958,519  140,508  5,269  2,904,664

 

Based on the votes set forth above, the shareholders approved the amendment to the Company’s Amended and Restated 2018 Equity Incentive Plan to increase the total number of shares of the Company’s common stock authorized for issuance under such plan by 1,500,000, to a total of 3,800,000 shares.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INSIGHT MOLECULAR DIAGNOSTICS INC.
     
Date: July 2, 2025 By: /s/ Peter Hong
  Name: Peter Hong
  Title: Vice President, General Counsel

 

 

 

FAQ

What insider transaction did Synchrony Financial (SYF) report?

Director Fernando Aguirre received 825 restricted stock units on 30 Jun 2025, as disclosed in a Form 4 filed 2 Jul 2025.

At what price were the RSUs valued in the SYF Form 4?

The RSUs were recorded at an indicative value of $66.74 per share, matching Synchrony Financial’s stock price on the grant date.

When will the newly granted RSUs to Aguirre vest?

All 825 RSUs vest on 30 Jun 2026, one year after the grant date.

How many SYF shares does Fernando Aguirre own after this grant?

Following the transaction, he holds 27,097 shares directly and 15,300 shares indirectly via family trusts.

Did the Form 4 report any sales or dispositions of SYF shares?

No. The filing only records an equity award (code A); there were no share sales or dispositions.

Is this Form 4 expected to impact Synchrony Financial’s share price?

Given the small size of the grant relative to SYF’s share count, analysts view the filing as non-material to valuation.
Oncocyte Corporation

NASDAQ:OCX

OCX Rankings

OCX Latest News

OCX Stock Data

77.22M
22.30M
22.27%
65.31%
1.07%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States
IRVINE